David Berglund

Director/Board Member at XNK Therapeutics AB

Health Technology

Profile

David Berglund has held director positions at CellProtect Nordic Pharmaceuticals AB and XNK Therapeutics AB.
He currently holds a director position at XNK Therapeutics AB.

David Berglund active positions

Companies	Position	Start
XNK Therapeutics AB XNK Therapeutics AB Pharmaceuticals: MajorHealth Technology XNK Therapeutics AB operates as a technology platform which leads research on NK cells at Karolinska Institutet in Stockholm. The company was founded in 2012 and is headquartered in Huddinge, Sweden.	Director/Board Member	03/10/2021
CellProtect Nordic Pharmaceuticals AB CellProtect Nordic Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Part of XNK Therapeutics AB, CellProtect Nordic Pharmaceuticals AB is a clinical-stage biotechnology company based in Huddinge, SE. CellProtect Nordic Pharmaceuticals is one of the pioneering companies in the field of cell therapy, developing unique and individualized natural killer (NK) cell-based cancer therapies. The Swedish company has built a tailor-made GMP clean room facility for manufacturing clinical products and is currently evaluating its lead product, evencaleucel, in a randomized, controlled, phase II study for the treatment of multiple myeloma. The company was founded in 2012 and the CEO is Johan Liwing.	Director/Board Member	-

All active positions of David Berglund

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of David Berglund's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
CellProtect Nordic Pharmaceuticals AB CellProtect Nordic Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Part of XNK Therapeutics AB, CellProtect Nordic Pharmaceuticals AB is a clinical-stage biotechnology company based in Huddinge, SE. CellProtect Nordic Pharmaceuticals is one of the pioneering companies in the field of cell therapy, developing unique and individualized natural killer (NK) cell-based cancer therapies. The Swedish company has built a tailor-made GMP clean room facility for manufacturing clinical products and is currently evaluating its lead product, evencaleucel, in a randomized, controlled, phase II study for the treatment of multiple myeloma. The company was founded in 2012 and the CEO is Johan Liwing.	Health Technology
XNK Therapeutics AB XNK Therapeutics AB Pharmaceuticals: MajorHealth Technology XNK Therapeutics AB operates as a technology platform which leads research on NK cells at Karolinska Institutet in Stockholm. The company was founded in 2012 and is headquartered in Huddinge, Sweden.	Health Technology